Oppenheimer Asset Management Inc. Grows Position in Genmab A/S Sponsored ADR $GMAB

Oppenheimer Asset Management Inc. raised its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 24.1% during the third quarter, according to its most recent filing with the SEC. The firm owned 315,862 shares of the company’s stock after purchasing an additional 61,311 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Genmab A/S were worth $9,687,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Osaic Holdings Inc. boosted its stake in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in Genmab A/S by 29.1% during the third quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock worth $57,000 after buying an additional 440 shares during the period. CWM LLC boosted its position in Genmab A/S by 28.3% during the 3rd quarter. CWM LLC now owns 2,306 shares of the company’s stock valued at $71,000 after acquiring an additional 509 shares in the last quarter. Captrust Financial Advisors increased its holdings in shares of Genmab A/S by 2.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock valued at $464,000 after acquiring an additional 526 shares during the period. Finally, Grandfield & Dodd LLC increased its holdings in shares of Genmab A/S by 1.6% in the 3rd quarter. Grandfield & Dodd LLC now owns 39,133 shares of the company’s stock valued at $1,200,000 after acquiring an additional 630 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $30.87 on Tuesday. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $35.43. The firm has a market capitalization of $19.83 billion, a price-to-earnings ratio of 13.14, a PEG ratio of 18.14 and a beta of 0.90. The stock’s 50-day simple moving average is $32.49 and its 200-day simple moving average is $29.56.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on GMAB shares. Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. HC Wainwright restated a “buy” rating and issued a $39.00 price target on shares of Genmab A/S in a report on Wednesday, January 28th. Truist Financial reaffirmed a “buy” rating and issued a $48.00 price objective (down previously from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $39.25.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.